Sunday, January 22, 2017 8:26:43 PM
"Simultaneously, weare already studying large scale synthesis of the nanomicelle polymer
backbones as well as the short-listed ligands against HSV and VZV, which should provide us a
head-start when we select the clinical candidate. We have scaled up many of the steps in the
production to ~200g to ~500g scales. Our scale up lab and manufacturing facility are well
equipped with reactor systems from as little as 500ml to as large as 30L already. We believe that
approximately 200g production batch size should be sufficient for the Safety/Tox Study batch as
well as for the Phase I and Phase II human clinical trials drug batches. We will need to
successfully produce at least two batches that meet our quality assurance criteria before we can
produce a clinical product batch."
I can never tell whether their batch sizes refer to the basic nanomicelle or the finished drugs. I shouldn't think that they would need 200g batches of individual drugs for testing...that seems obvious...but could they really STILL be referring to the basic nanomicelle here?:
"We have scaled up many of the steps in the
production to ~200g to ~500g scales."
No real need to respond. It's only curiosity on my part. I'm just amazed that I'm still confused by the same things that confused me a couple of years ago.
‘There are none so blind as those who will not see. The most deluded people are those who choose to ignore what they already know.’
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM